← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Curza Inc
Salt Lake City, UT
$15,536,722
Total funding
6
Grants
Funding over time
peak $3M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,536,722 · 6
By mechanism
R44$9,858,431 · 4
R01$5,079,521 · 1
R43$598,770 · 1
Investigators at Curza Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$1,206,566
R01 · FY2019 · AI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$1,193,671
R01 · FY2020 · AI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$1,045,564
R01 · FY2021 · AI
A new class of broad-spectrum antibacterials for treating MDR infections$1,000,000
R44 · FY2022 · AI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens$1,000,000
R44 · FY2023 · AI
New oral antibiotics focused on treating MDR Gram-negative infections$1,000,000
R44 · FY2024 · AI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens$1,000,000
R44 · FY2024 · AI
New oral antibiotics focused on treating MDR Gram-negative infections$1,000,000
R44 · FY2025 · AI
A new class of broad-spectrum antibacterials for treating MDR infections$1,000,000
R44 · FY2021 · AI
A new class of broad-spectrum antibacterials for treating MDR infections$1,000,000
R44 · FY2020 · AI
A new class of antibiotic to address Antimicrobial Resistance$999,998
R44 · FY2024 · AI
A new class of antibiotic to address Antimicrobial Resistance$999,997
R44 · FY2025 · AI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$866,989
R01 · FY2017 · AI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens$858,436
R44 · FY2025 · AI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$766,731
R01 · FY2018 · AI
Natural product-inspired antibacterials with unique ribosomal binding$300,000
R43 · FY2016 · AI
Natural product-inspired antibacterials with unique ribosomal binding$298,770
R43 · FY2017 · AI